NCT06092060View on ClinicalTrials.gov

The Effect of a Multistrain Probiotic on Metformin Tolerance and Efficacy With Microbiota and Stool Metabolome in Insulin-resistant Women - a 12-week Randomized, Placebo-controlled, Double-blind Study

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

July 20, 2023

Conditions
Insulin Resistance
Interventions
DIETARY_SUPPLEMENT

the group GS (probiotic)

The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24

DIETARY_SUPPLEMENT

the group GP (placebo)

The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.

Trial Locations (1)

61-871

Poznan University of Physical Education, Poznan

All Listed Sponsors
lead

Poznan University of Physical Education

OTHER

NCT06092060 - The Effect of a Multistrain Probiotic on Metformin Tolerance and Efficacy With Microbiota and Stool Metabolome in Insulin-resistant Women - a 12-week Randomized, Placebo-controlled, Double-blind Study | Biotech Hunter | Biotech Hunter